Systematic Review of Modern Case Series of Squamous Cell Cancer Arising in a Chronic Ulcer (Marjolin’s Ulcer) of the Skin

Mohamed A. Abdi, MD1; Michael Yan, MD1; and Timothy P. Hanna, MD, MSc, PHD1,2

PURPOSE Marjolin’s ulcer is an aggressive cutaneous malignancy that arises in chronic nonhealing wounds. A review of modern series describing Marjolin’s ulcer would be helpful in defining optimal management strategies and expected outcomes.

METHODS A systematic review was performed on October 18, 2018, by querying Medline and EMBASE. Key inclusion criteria were as follows: human studies, English language, published in 2000 or later, >10 patients, and at least 80% of the patients having squamous cell carcinoma (SCC) histology.

RESULTS There were 599 patients in 14 case series from 10 countries; 82% of patients were from low-income and middle-income countries, and 48% were women. Overall, 65% of the ulcers were preceded by burns. Mean latency ranged from 11 years to 41 years (median, 28 years). Lower extremities were the most common site (62%). Differentiation was reported as well differentiated (64%), moderately differentiated (27%), or poorly differentiated (9%). Almost one third of cases were clinically node positive, though only 7% of all cases (24 of 334) were confirmed to be pathologically involved. Distant metastasis rates were reported in only 7 series, with median rate of 5% (range, 0%-27%). The main treatment modality was surgical excision (71%), followed by amputation (24%), primary radiotherapy (2%), and chemotherapy (1%). Outcomes data varied in content and quality. Mortality rates were 12%, 24%, and 37% in the three series reporting between 2 and 3 years of follow-up.

CONCLUSION Marjolin’s ulcer with SCC histology is an aggressive cancer with a notable potential for lymph node metastasis and distant metastasis. Comprehensive staging is recommended, with management optimally having a multidisciplinary context. Low- and middle-income countries are overrepresented in reports of Marjolin’s ulcer, and there may be opportunities for prevention and early detection.

INTRODUCTION Marjolin’s ulcer is an aggressive cutaneous malignancy that arises in chronic nonhealing wounds. It is uncommon in high-income country settings, though it may be more common in lower-resource settings, given the role of chronic wounds arising from situations that involve suboptimal management at time of primary injury.1 The natural history of a Marjolin’s ulcer includes the initial insult, which results in a nonhealing or recurrent ulcer.2,3 The latency period is defined as the time from initial injury to the diagnosis of Marjolin’s ulcer. The average latency period varies widely, but it is typically greater than a decade.2,3 The cause of the malignant transformation is not well defined. Squamous cell carcinoma (SCC) is the most common histology for Marjolin’s ulcer.2,4 There are limited data that systematically review management and outcome in the era of cross-sectional imaging or more advanced forms of systemic therapy and radiotherapy. We set out to review clinical features of Marjolin’s ulcer with SCC histology in modern case series so that management strategies and expected outcomes could be better defined.

METHODS Study Eligibility To identify all published case series on Marjolin’s ulcer, we performed a systematic review using the Ovid database and including EMBASE and Medline. The goal was to identify modern case series describing contemporary management, so only studies published in the year 2000 or later were retained, with year of individual patient diagnosis ranging from January 1, 1995, to October 18, 2018. Additional inclusion criteria were English language; >10 patients; inclusion of information on staging, management, and/or
outcomes; and at least 80% of the patients having SCC histology.

Search Algorithm
Keywords were used to simultaneously search EMBASE and Medline: "marjolin," "scar neoplasm," "scar cancer," or "chronic ulcer." Details of the search strategy are provided in Appendix Figure A1. Study results were supplemented by hand searches of key article reference lists for other articles.

Data Extraction
After completing the search algorithm, the identified studies were reviewed. Data were abstracted using a standardized form. Abstracted variables for each study were as follows: number of patients from each study, study period, mean age at diagnosis, proportion of patients who were female, mean latency period, percent SCC histology, grade, site of lesion, size of ulcer, injury type, treatment types used (surgery, chemotherapy, or radiation), use of imaging, presence of metastasis at diagnosis, use of lymph node dissection, outcomes, recurrences, and re-treatment.

Data Analysis
The abstracted data were reviewed by three independent investigators (M.A., M.Y., T.P.H.). Consensus was reached when there were differences in abstracted data. Data were summarized in the form of categoric variables, frequency tables, and summary figures. Given heterogeneity and limited availability of study data, meta-analysis of outcomes was not deemed feasible or appropriate.

RESULTS
The systematic review was performed on October 18, 2018. Details of the literature search are provided in Figure 1. Fourteen case series met inclusion criteria.

Demographic Data
There were 599 patients total in the 14 identified series (Table 1). Women were 48% of the patient group (n = 289). The mean age at diagnosis of Marjolin’s ulcer ranged in studies from 30 to 76 years, with a median value of 51 years. Series included patients from Das4 (n = 46 patients), Smith6 (n = 21), Shen12 and Yu1 (n = 68), Combermale13 (n = 80), Reich-Schupke10 (n = 30), Shala17 and Sadegh Fazeli15 (n = 102), Kadir16 (n = 36), Chalya8 (n = 56), and Karasoy Yesilada,9, Aydogdu,7 and Oruc14 (n = 112; Fig 2). Except for France and Germany, all series were for patients (n = 489) from low- or middle-income countries (LMICs) according to the World Bank Country Income Classification for 2010.5

Wound Characteristics
In the identified case series, burn injury was the most common form of injury, occurring in 65% of all cases with a described mechanism (387 of 598 patients). This was followed by venous ulcers (115 of 598 patients) and trauma (44 of 598 patients). The remaining cases could be classified as infection (14 of 598 patients) or other causes (38 of 598 patients; eg, human bite, pressure sore, diabetic foot, radiation, surgical scar, or electrical injury). Notably, all cases reported in the 2 high-income country case series involved venous ulcers (n = 105). The most common site of Marjolin’s ulcer for cases with a reported site (n = 589) was the lower extremities, at 62% (366 of 589 patients), followed by scalp and face at 16% (95 of 589 patients), upper extremities at 12% (72 of 589 patients), and torso at 10% (56 of 589 patients). Overall, 92% of the lesions were SCC. Differentiation was reported for 74% (441 of 599 patients). The majority were well differentiated (64%), with the remainder moderately differentiated (27%) or poorly differentiated (including undifferentiated or anaplastic, 9%).

Clinical Presentation
Cases typically had a nonhealing ulcer that has been present for many years. Mean latency ranged from 11 years to 41 years, with a median value of 28 years. The median value of mean latency was 22 years for the case series from high-income countries and was 29 years for the series from LMICs.
Imaging

Information on imaging use was incomplete when provided and was not reported in 8 of 14 series. All series reporting on imaging used cross-sectional imaging (computed tomography, magnetic resonance imaging, or positron emission tomography/computed tomography). In most cases, it was not specified how many patients in the series had disease staged with these techniques. Plain film x-rays and/or ultrasound were used in all series reporting on imaging.

Disease Extent at Diagnosis

When reported, the involved primary areas were large. The 2 series reporting median ulcer size reported a median of 16 cm (range, 7-32 cm) and 14 cm (range, 5-30 cm), respectively.6,7 The 2 series reporting on median tumor size reported a median of 8 cm (range, 2-16 cm) and 10 cm (range, 2-25 cm), respectively.8,9

The presence of deep invasion was described in 4 series. Direct extension to muscle or bone occurred in a median of 36% of cases, ranging from 3% of cases in a high-income country series to 95% in an LMIC series.6,10,11,13

Lymph node status was reported for 507 patients from 12 case series (Table 2). Almost a third (30%) of cases was assessed to have clinical involvement—though, among the 8 series reporting on pathologic status of lymph nodes considered clinically involved, only 7% of patients (24 of 334 patients) had pathologically involved disease.1,3,6,9,10,12-14 Specifically, only 28% of patients undergoing biopsy and/or dissection for clinically involved nodes had pathologic involvement (24 of 85 patients). There was little difference in reported lymph node status between the 2 high-income country cases series and the 12 series from LMICs. Clinical node positive rates were 32% and 30% of patients (P = .69), and pathologic node positive rates were 6% and 8% (P = .51), for high-income countries and LMICs, respectively. Compared with later series (earliest case reported from 2000-1010), earlier series (earliest case report date, 1995-1999) demonstrated higher rates of clinical node positivity (44% v 20%; P < .001) despite similar pathologic node positive rates (6% v 4%; P = .30).

Distant metastasis at diagnosis was described in 7 series, representing 342 patients; 8% had distant metastasis (29 of
### TABLE 1. Primary Treatment of Marjolin’s Ulcer

| Author | Country (World Bank Country Classification) | Earliest Case Report Date | Cohort | Cohort With Treatment Information | Excision | Amputation | Radiotherapy (no surgery/chemotherapy) | Chemotherapy (no surgery/radiotherapy) | No Treatment |
|--------|--------------------------------------------|---------------------------|--------|-----------------------------------|----------|------------|---------------------------------------|----------------------------------------|-------------|
| Sadegh Fazeli15 | Iran (UM) | 1995-1999 | 83 | 0 | NR | NR | NR | NR | NR | NR |
| Combemale13 | France (H) | 1995-1999 | 80 | 51 | 12 | 29 | 3 | 1 | 6 |
| Smith6 | Brazil (UM) | 1995-1999 | 21 | 21 | 0 | 19 | 0 | 0 | 2 |
| Shahla17 | Iran (UM) | 1995-1999 | 19 | 19 | 0 | 19 | 0 | 0 | 0 |
| Karasoy Yesilada9 | Turkey (UM) | 1995-1999 | 34 | 34 | 28 | 6 | 0 | 0 | 0 |
| Aydoğan7 | Turkey (UM) | 1995-1999 | 15 | 15 | 12 | 0 | 30 | 0 | 0 |
| Oruç14 | Turkey (UM) | 2000-2004 | 63 | 63 | 63 | 0 | 0 | 0 | 0 |
| Kadir16 | Iraq (LM) | 2000-2004 | 48 | 47 | 44 | 3 | 0 | 0 | 0 |
| Tahir11 | Nigeria (LM) | 2000-2004 | 36 | 32 | 18 | 9 | NR | NR | 5 |
| Chalya8 | Tanzania (L) | 2000-2004 | 56 | 48 | 42 | 6 | NR | NR | NR |
| Shen12 | China (UM) | 2000-2004 | 51 | 43 | 28 | 13 | 1 | 0 | 1 |
| Das3 | Bangladesh (L) | 2000-2004 | 46 | 46 | 45 | 1 | NR | 0 | 0 |
| Yu1 | China (UM) | 2005-2010 | 17 | 17 | 17 | 0 | NR | 0 | 0 |
| Reich-Schupke10 | Germany (H) | 2005-2010 | 30 | 29 | 23 | 6 | NR | NR | NR |
| Total | | | 599 | 465 | 332 | 111 | 7 | 1 | 14 |

Abbreviations: H, high income; L, low income; LM, lower-middle income; NR, not reported; UM, upper-middle income.

aAll patients underwent surgery. No additional details were provided.

bOne patient received radiotherapy and chemotherapy.
342 patients). The median rate reported in the 7 series was 5% (range, 0% for Germany and China to 27% for Tanzania).

Treatment Modalities
Surgery was the primary modality of therapy in all series (Table 1). For the 465 patients with treatment information, surgical excision was used in 71% (n = 332), followed by amputation in 24% (n = 111), primary radiotherapy in 2%, and chemotherapy in < 1%. Three percent of patients did not receive active treatment; 58% of surgery patients received amputation in earlier series (1995-1999 earliest report), compared with 12% for later series (2000-2010 earliest report, P < .001).

In some cases, radiotherapy was used in addition to other treatments. For example, Karasoy Yesilada et al.13 used adjuvant radiotherapy in 18 of 34 cases. In total, of 465 patients with treatment information, 41 patients received radiotherapy as part of their primary management, though only 7 received it without surgery. Three series reported radiotherapy use without quantifying the number of cases.13,18 Reported indications were for inoperable tumors, advanced cases, and postoperative radiotherapy. Chemotherapy was rarely used as part of initial management, with only 9 receiving it as part of their primary management and only 1 patient receiving chemotherapy alone.

Outcomes
All but 2 series reported on cancer outcomes. These outcomes varied.10,15 Seven series reported on mortality; 7, on local recurrence; and 4, on distant recurrence. No series reported Kaplan-Meier survival statistics. Only 2 series reported lymph node recurrence, and the 4 reported nodal recurrences were accompanied by local (n = 2) or distant (n = 2) metastasis.3,12 Outcome reporting was heterogeneous in terms of number of endpoints, chosen endpoints, and length of follow-up, making meta-analysis inappropriate (Table 3).

Mortality ranged from 7% to 73%, though intensity of follow-up was usually unclear. Duration of follow-up was summarized as mean or median in only 3 series (all results, between 2 and 3 years). Mortality rates for these 3 series were 12%, 24%, and 37%.1,12,13 Mortality by stage was worse reported mortality in earlier series (1995-1999), with a range of 37%-73%, compared with later series (2000-2010; range, 7%-24%). Results were not pooled, given the limited information on follow-up.

Local recurrence in 7 reporting series ranged from 6% to 67% (Table 3). Two series reported on outcomes after local recurrence.7,16 All 24 patients in these 2 series with local recurrence died of cancer. Distant recurrence ranged from 0% to 12% in 4 reporting series (Table 3).

DISCUSSION
Marjolin’s ulcer is an aggressive skin malignancy that occurs after a chronic nonhealing wound. We observed that it is often found in an advanced state, with a propensity for
| Author | Country (World Bank Country Classification)$^a$ | Earliest Case Report Date | Clinical Node Positive | Pathologic Node Positive | Total Patient Population |
|--------|-----------------------------------------------|---------------------------|------------------------|--------------------------|--------------------------|
| Sadegh Fazeli$^{15}$ | Iran (UM) | 1995-1999 | 43 | NR | 62 |
| Combe male$^{13}$ | France (H) | 1995-1999 | 35 | 7 | 80 |
| Smith$^6$ | Brazil (UM) | 1995-1999 | 6 | 1 | 21 |
| Shahla$^{17}$ | Iran (UM) | 1995-1999 | 1 | NR | 19 |
| Karasoy Yesilada$^9$ | Turkey (UM) | 1995-1999 | 10 | 4 | 34 |
| Oruç$^{14}$ | Turkey (UM) | 2000-2004 | 12 | 4 | 63 |
| Tahir$^{11}$ | Nigeria (LM) | 2000-2004 | 12 | NR | 36 |
| Chalya$^8$ | Tanzania (L) | 2000-2004 | 18 | NR | 56 |
| Shen$^{12}$ | China (UM) | 2000-2004 | 3 | 8 | 43 |
| Das$^3$ | Bangladesh (L) | 2000-2004 | 12 | 0 | 46 |
| Yu$^1$ | China (UM) | 2005-2010 | 1 | 0 | 17 |
| Reich-Schupke$^{10}$ | Germany (H) | 2005-2010 | 0 | 0 | 30 |
| Total | | | 153 | 24 | 507 |

Abbreviations: H, high income; L, low income; LM, lower-middle income; NR, not reported; UM, upper-middle income.

$^a$World Bank Country Income Classifications$^5$ for 2010, accessed July 4, 2019: low income (L), $\leq$ $1,005; lower-middle income (LM), $1,006$-$3,975; upper-middle income (UM), $3,976$-$12,275; high income (H), $>12,275.$
| Author         | Country (World Bank Country Classification) | Earliest Case Report Date | Mortality               | Local Recurrence | Distant Recurrence | Overall/Any-Site Recurrence | Other Recurrence or Mortality |
|----------------|--------------------------------------------|---------------------------|-------------------------|------------------|--------------------|-----------------------------|-------------------------------|
| Sadegh Fazeli 15 | Iran (UM)                                  | 1995-1999                 | NR                      | NR               | NR                 | NR                          | NR                            |
| Combemale 13    | France (H)                                 | 1995-1999                 | 37% (19/51; mean follow-up, 2.3 years) | NR               | NR                 | NR                          | Mortality: 27% (11/41) for stage I, 80% for nodal and/or visceral metastasis (8/10); cause of death not specified |
| Smith 6         | Brazil (UM)                                | 1995-1999                 | 42% (8/19) died of any cause, 21% (4/19) died of cancer, 2 were lost to follow-up (refused surgery); length of follow-up not provided | NR               | NR                 | NR                          | Death or recurrence in 42% (8/19; length of follow-up not stated) |
| Shahla 17       | Iran (UM)                                  | 1995-1999                 | NR                      | NR               | NR                 | No recurrence or metastasis with mean 4-year follow-up | NR                            |
| Karasoy Yesilada 9 | Turkey (UM)                               | 1995-1999                 | 6% (2/34)               | NR               | 17% (10 years of follow-up) | NR                          | NR                            |
| Aydogdu 7       | Turkey (UM)                                | 1995-1999                 | 73% (11/15, within 8-20 months) | 67% (8/12)       | NR                 | 67% (8/12)                  | 100% (8/8) local recurrences died of cancer; mean survival, 13.3 months |
| Oruc 14         | Turkey (UM)                                | 2000-2004                 | NR                      | 14% (9/63)       | 3% (2/63)          | NR                          | NR                            |
| Kadir 16        | Iraq (LM)                                  | 2000-2004                 | 33% (16/48)             | NR               | NR                 | NR                          | NR                            |
| Tahir 11        | Nigeria (LM)                               | 2000-2004                 | 8% (3/36; follow-up, 3-36 months) | NR               | 6% (2/36)          | 17% (6/36)                  | NR                            |
| Chalya 8        | Tanzania (L)                               | 2000-2004                 | 7% (All documented deaths appeared to have occurred during first admission.) | NR               | NR                 | NR                          | NR                            |
| Shen 12         | China (UM)                                 | 2000-2004                 | 12% (5/43; median follow-up, 2 years; range, 1-8 years) | 7% (3/43)        | 12% (5/43)         | 12% (5/43)                 | Nodal recurrence in 2/43, accompanied by lung metastasis in both cases |
| Das 3           | Bangladesh (L)                             | 2000-2004                 | NR                      | 13% (6/46, with 2 also nodal recurrence) | 0% (0/46)          | 13% (6/46; within 6 months) | NR                            |
| Yu 1            | China (UM)                                 | 2005-2010                 | 24% (4/17; all within 1 year, all of cancer; mean follow-up, 2.9 years; range, 1-6 years) | 6% (1/17)        | NR                 | NR                          | One patient developed a new separate primary. |
| Reich-Schupke 10 | Germany (H)                                | 2005-2010                 | NR                      | NR               | NR                 | NR                          | NR                            |

Abbreviations: H, high income; L, low income; LM, lower-middle income; NR, not reported; UM, upper-middle income.
lymph node metastasis and distant metastasis, and with substantial mortality. Reported cases are most often from LMICs. To tailor treatment, careful staging with cross-sectional imaging is important, and careful consideration of the relevant draining nodal basin(s) should be undertaken on exam. A minority of series reported the use of cross-sectional imaging. We hypothesize that this reflects the lack of use of such imaging in many resource-limited settings. The available data on the clinical occurrence of lymph node metastasis and distant metastasis at diagnosis suggest that there may be more cases with occult metastasis that are clinically undetected. Cross-sectional imaging, such as computed tomography or magnetic resonance scans, would help better define the clinical extent of disease at diagnosis. Biopsy of suspicious lymphadenopathy appears important. We observed that only 28% of patients undergoing biopsy and/or dissection for clinically involved nodes had pathologic involvement (24 of 85 patients). The occurrence of lymphadenopathy without pathologic involvement may relate to the chronic nature of the wound preceding the development of malignancy. For cases without clinical evidence of lymph node metastasis, the role of sentinel lymph node biopsy is not well defined. In adequately resourced settings, additional investigation of the utility of sentinel node biopsy in Marjolin’s ulcer would be worthwhile.

Surgery forms the backbone of treatment of Marjolin’s ulcer. We observed increasing use of excision, rather than amputation, over time. Whether this relates to improvements in resource availability among the identified series, a change in philosophy of local management, or a change in the extent of disease over time is unclear. We note the importance of both clinical examination and imaging in determining the extent of disease when a more radical local procedure is undertaken. As noted, there was a sizeable risk of both lymph node metastasis and distant metastasis in the identified series.

There may be opportunities for prevention and early detection of Marjolin’s ulcer, especially in LMICs. We note the divergence in injury mechanism between LMIC (predominantly burns) and high-income country reports (all venous ulcers). The predominance of burn injury may point to the need for optimizing initial wound management. Because of the lack of patient and system resources, deep wounds may be allowed to heal by secondary intention rather than getting proper medical care and skin grafting.5,8 The latency period in all series was lengthy (median, 28 years), though it was longer in LMICs (median, 29 years) than in high-income countries (median, 22 years). Though the difference may relate to differences in disease factors or patient factors, this difference in latency period raises the question as to whether substantial improvements in early detection of Marjolin’s ulcer may be possible in LMICs. Increased access to public health education, transportation, and lower-cost interventions might allow more patients to be treated earlier; to avoid the notable and often severe morbidity of chronic wounds; and, probably in some cases, to avoid development of Marjolin’s ulcer.

The role of radiotherapy and systemic therapy for Marjolin’s ulcer remains unclear. Local control is important for this condition. In the 2 series reporting outcomes after local recurrence, all patients died.7,16 However, there was insufficient data in the identified series to evaluate the safety and efficacy of adjuvant radiotherapy after excision. This may relate to limitations in resources and access to these treatments. It also may relate to a justifiable hesitancy to radiate a poorly vascularized chronic wound site, even after surgical excision. Response rates to radiotherapy for gross disease are also unclear, according to the series we found. We found that areas of involvement with Marjolin’s ulcer are often quite large. Though the relationship of size and outcome with radiotherapy is unknown for Marjolin’s ulcer, larger lesion size and/or advanced disease for cutaneous SCC and other advanced skin cancers is associated with lower control rates with radiotherapy.18-20 For example, in a series of 88 patients with clinical T4 nonmelanoma skin cancers treated with radical radiotherapy, the local control was only 53% at 5 years; 44% of lesions treated were SCC, and 12% were basosquamous.18 Another series of patients with advanced head and neck skin SCC were treated with concurrent chemoradiation.20 Eleven patients had disease > 5 cm. Only approximately half of the evaluable patients (10 of 19 patients) achieved a complete response with this aggressive approach.

The role of systemic therapy for Marjolin’s ulcer is not well defined in the literature, and its use is quite scattered. The benefit of concurrent systemic therapy with radiotherapy is unclear, as is the potential use of systemic therapy (and/or radiotherapy) as a neoadjuvant treatment to facilitate surgical removal. The potential benefits of immunotherapy also require investigation. Cemiplimab is now approved for advanced and metastatic cutaneous SCC. In a phase II study of 59 patients with metastatic cutaneous SCC, a response rate of 47% was observed.21 The applicability to Marjolin’s ulcer is not clear.

Our study provides, to our knowledge, the largest analysis of contemporary patients with Marjolin’s ulcer, with data on 599 patients. For the first time, to our knowledge, an international perspective is provided, comparing reports from LMICs and high-income countries.

There are limitations. Available case series often had incomplete data. There was a lack of well-defined follow-up over an extended period, and there was variable reporting of outcomes. Thus, data were not analyzed via Kaplan-Meier statistics. There was probably only limited use of cross-sectional imaging for staging and follow-up, meaning that our estimates of disease extent at diagnosis, and recurrence rates, are likely to be underestimates of actual rates. There are also probably differences in extent of disease between cases seen in referral centers and cases that were never referred to a specialty center. Our systematic review was limited to English only. Limitations
excepted, this review provides valuable insights into elements of diagnosis, treatment, and outcome of this disease. It also emphasizes the importance of rigorously conducted clinical case series and registry studies for rare diseases.

Marjolin’s ulcer is a cutaneous malignancy with a notable risk of lymph node metastasis and distant metastasis, suggesting the need for cross-sectional radiologic staging. The optimal role of radiotherapy and systemic therapy requires additional investigation. In identified case series, patients are most often from LMICs, where medical resources can be limited. The injury causing the chronic wound is most often a burn injury, and the wound usually has been present for decades before the diagnosis of Marjolin’s ulcer. There may be opportunities for prevention and early detection.

**AFFILIATIONS**

1. Department of Oncology, Queen’s University, Kingston, Ontario, Canada
2. Division of Cancer Care and Epidemiology, Cancer Research Institute at Queen’s University, Kingston, Ontario, Canada

**CORRESPONDING AUTHOR**

Timothy Hanna, MD, MSc, PhD, Division of Cancer Care and Epidemiology, Cancer Research Institute at Queen’s University, 10 Stuart St, 2nd Level, Kingston, Ontario K7L3N6 Canada; Twitter: @HannaRadOnc; e-mail: tim.hanna@kingstonhsc.ca.

**EQUAL CONTRIBUTION**

M.A.A. and M.Y. contributed equally as co-primary authors.

**AUTHOR CONTRIBUTIONS**

Conception and design: All authors
Collection and assembly of data: All authors
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Agree to be accountable for all aspects of the work: All authors

**REFERENCES**

1. Yu N, Long X, Lujan-Hernandez JR, et al: Marjolin’s ulcer: A preventable malignancy arising from scars. World J Surg Oncol 11:313, 2013
2. Copcu E: Marjolin’s ulcer: A preventable complication of burns? Plast Reconstr Surg 124:156e-164e, 2009
3. Das KK, Chakraborty A, Rahman A, et al: Incidences of malignancy in chronic burn scar ulcers: Experience from Bangladesh. Burns 41:1315-1321, 2015
4. Pekarek B, Buck S, Osher L: A comprehensive review on Marjolin’s ulcers: Diagnosis and treatment. J Am Col Certif Wound Spec 3:60-64, 2011
5. World Bank: Country income classifications for 2010. http://databank.worldbank.org/data/download/site-content/OGHIST.xls.
6. Smith J, Mello LF, Nogueira Neto NC, et al: Malignancy in chronic ulcers and scars of the leg (Marjolin’s ulcer): A study of 21 patients. Skeletal Radiol 30:331-337, 2001
7. Aydoğdu E, Yıldırım S, Aköz T: Is surgery an effective and adequate treatment in advanced Marjolin’s ulcer? Burns 31:421-431, 2005
8. Chalya PL, Mabula JB, Rambau P, et al: Marjolin’s ulcers at a university teaching hospital in Northwestern Tanzania: A retrospective review of 56 cases. World J Surg Oncol 10:38, 2012
9. Karasoy Yesilada A, Zeynep Sevim K, Özgur Sucu D, et al: Marjolin ulcer: Clinical experience with 34 patients over 15 years. J Cutan Med Surg 17:327-333, 2013
10. Reich-Schupke S, Doerler M, Wollina U, et al: Squamous cell carcinomas in chronic venous leg ulcers: Data of the German Marjolin Registry and review. J Dtsch Dermatol Ges 13:1006-1013, 2015
11. Tahir C, Ibrahim BM, Terna-Yawe EH, et al: The increasing burden of Marjolin’s ulcer in North Eastern Nigeria: A 10 year study and review of literature. Nigerian Journal of Plastic Surgery 8:14-18, 2012
12. Shen R, Zhang J, Zhang F, et al: Clinical characteristics and therapeutic analysis of 51 patients with Marjolin’s ulcers. Exp Ther Med 10:1364-1374, 2015
13. Combenale P, Bousquet M, Kanitakis J, et al: Malignant transformation of leg ulcers: A retrospective study of 85 cases. J Eur Acad Dermatol Venereol 21:935-941, 2007
14. Oruç M, Kankaya Y, Sungur N, et al: Clinicopathological evaluation of Marjolin ulcers over two decades. Kaichiun J Med Sci 33:327-333, 2017
15. Sadegh Fazeli M, Lebaschi AH, Hajirostam M, et al: Marjolin’s ulcer: Clinical and pathologic features of 83 cases and review of literature. Med J Islam Repub Iran 27:215-224, 2013
16. Kadir AR: Burn scar neoplasms. Ann Burns Fire Disasters 20:185-188, 2007
17. Shahla A: An overview of heel Marjolin’s ulcer. J Laryngol Otol 130:1006-1013, 2015
18. Al-Othman MO, Mendenhall WM, Amdur RJ: Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage. Am J Otolaryngol 22:387-390, 2001
19. Kwan W, Wilson D, Moravan V: Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 60:406-411, 2004
20. Nottage M.K., Lin C, Hughes BG, et al: Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 39:679-683, 2017
21. Migden M.R., Rischin D, Schmuts BD, et al: PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341-351, 2018

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/site/misc/authors.html.

Mohamed A. Abdi
Consulting or Advisory Role: Epic

Timothy P. Hanna
Research Funding: Roche

No other potential conflicts of interest were reported.
APPENDIX

FIG A1. Search strategy for modern series of Marjolin’s ulcer.